Rheumatology - European Medical Journal

This site is intended for healthcare professionals

Continue

Rheumatology

Filter
5 Feb 2021

Could Colchicine Cut COVID-19 Hospital Admissions and Deaths?

COLCHICINE, an anti-inflammatory oral drug commonly used for the treatment of gout and rheumatic diseases, has reportedly been shown to significantly…
5 Feb 2021

Osteopontin and Lung Scarring in Scleroderma

OSTEOPONTIN (OPN), a protein known to function as an immune system modulator and play a role in tissue regeneration, may be responsible for driving lung…
30 Oct 2020

EULAR Releases First Core Data for Rheumatology in Pregnancy

THE EUROPEAN League Against Rheumatism (EULAR) has collated and released its first consensus-based recommendations for prospective pregnancy registries…
30 Oct 2020

Cytokine Storm Criteria Enable Early COVID-19 Diagnosis

CYTOKINE storm is the term given to immune responses triggered by escalated infections, such as in the coronavirus disease (COVID-19). Severe immune…
31 Jul 2020

Novel Opioid Provides Less Addictive Pain Relief and May Slow Osteoarthritis Progression

ADDICTIVE opioids are routinely taken by many people with arthritis to manage their pain. Kappa opioid receptor (KOR) agonists are known to be less…
31 Jul 2020

Is Tocilizumab Beneficial to Critically Ill COVID-19 Patients?

Tocilizumab, an immunosuppressant originally developed as a rheumatoid arthritis treatment, has demonstrated further benefits in treating patients…
Initial Results of the COVID-19 Global Rheumatology Alliance Provider Registry
5 May 2020

Initial Results of the COVID-19 Global Rheumatology Alliance Provider Registry

COVID-19, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is of particular concern to patients who are immunocompromised…
NRAS: 'Being Diagnosed with Rheumatoid Arthritis'
5 May 2020

New Evidence Linking Gout and Risk of Heart Failure

GOUT has been linked to increased risk of incident heart failure in older adults according to a recent study by Dr Lisandro Colantonio and colleagues…
We’ve noticed you’re accessing
from North/South America.